CHFR and lung carcinoma: We have previously reported that advanced lung cancer patients with CHFR deficient lung cancers have remarkably high clinical benefits rates following taxane-based first line chemotherapy (81% vs 48%, p = 0.03) and significantly improved overall-survival (HR = 0.24; 95% CI, 0.1–0.58%; P = 0.002) suggesting that in this setting, taxanes can be considered targeted therapy against CHFR-low expressing tumors [6].